Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Homestead Advisers Corp

Homestead Advisers Corp grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 39.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 50,500 shares of the medical equipment provider’s stock after buying an additional 14,300 shares during the quarter. Homestead Advisers Corp’s holdings in Lantheus were worth $4,518,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in Lantheus in the third quarter valued at approximately $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the 4th quarter valued at approximately $27,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. Parkside Financial Bank & Trust boosted its holdings in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after buying an additional 280 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in Lantheus by 118.0% during the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider’s stock valued at $91,000 after buying an additional 551 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ LNTH opened at $98.43 on Thursday. The stock’s 50 day simple moving average is $93.01 and its 200-day simple moving average is $96.47. The company has a market cap of $6.74 billion, a PE ratio of 16.38 and a beta of 0.38. Lantheus Holdings, Inc. has a 1-year low of $58.16 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial increased their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Finally, The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.